Nuformix plc (LON:NFX – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The company traded as low as GBX 0.14 ($0.00) and last traded at GBX 0.15 ($0.00), with a volume of 2880428 shares traded. The stock had previously closed at GBX 0.15 ($0.00).
Nuformix Stock Performance
The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17. The company has a market cap of £1.23 million, a PE ratio of -1.63 and a beta of 1.22. The stock’s 50 day simple moving average is GBX 0.17 and its two-hundred day simple moving average is GBX 0.19.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- Earnings Per Share Calculator: How to Calculate EPS
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Buy P&G Now, Before It Sets A New All-Time High
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
